South Korean pharmaceutical company Boryung announced that its production facility for anti-cancer injections in Yesan, South Chungcheong Province, has received European Union GMP certification.
The facility underwent review by the German government's drug licensing agency in Hamburg from September to October last year and was granted the certification, which evaluates the management standards in all production processes from raw material procurement to manufacturing, quality control, and shipment.
Boryung previously received GMP approval from South Korea's Ministry of Food and Drug Safety in 2020.
"We are committed to making the Yesan plant a major step forward in Boryeong's global expansion through continuous efforts in manufacturing and quality management," said Park Kyung-sook, head of Boryung's production and quality division.
Write to Jeong Min Nam at
peux@hankyung.com
